Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
8-K
Shareholder vote
confidence 95%
filed 2026-07-22
Item 5.07
This Item 5.07 disclosure reports the results of the Company's 2026 Annual Meeting of Members held on July 17, 2026, including voting outcomes on two matters: (1) re-election of three Class I directors (David R. Adler, Sheila A. Finnerty, and Andrew W. Tarica) with unanimous approval (3,753,190 votes for, 0 withheld), and (2) ratification of Deloitte & Touche LLP as independent auditor with unanimous approval (3,753,190 votes for, 0 against). The disclosure directly matches the shareholder_vote_results category as it presents formal voting results from an annual meeting of security holders.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 95%
filed 2026-07-22
Item 5.07
This Item 5.07 disclosure reports the results of the Company's 2026 Annual Meeting of Members held on July 17, 2026, including voting outcomes on two matters: (1) re-election of three Class I directors (David R. Adler, Sheila A. Finnerty, and Andrew W. Tarica) with unanimous approval (3,224,700 votes for, 0 withheld), and (2) ratification of Deloitte & Touche LLP as independent auditor with overwhelming approval (3,217,200 for, 7,500 against). This is a classic shareholder vote results disclosure required under Item 5.07.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 95%
filed 2026-07-22
Item 5.07
This Item 5.07 disclosure reports the results of TCW Direct Lending VII LLC's 2026 Annual Meeting of Members held on July 17, 2026. The filing presents voting outcomes for two matters: (1) re-election of three Class II directors (David R. Adler, Sheila A. Finnerty, and R. David Kelly) with unanimous approval (9,099,650 votes for, 0 withheld), and (2) ratification of Deloitte & Touche LLP as independent auditor with overwhelming approval (9,097,650 for, 2,000 against). This is a straightforward shareholder vote results disclosure, material to investors as it confirms board composition and auditor selection.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 95%
filed 2026-07-22
Item 5.07
This Item 5.07 disclosure reports the results of TCW Direct Lending LLC's 2026 Annual Meeting of Members held on July 17, 2026, including voting outcomes on three matters: re-election of a Class III director (David R. Adler), ratification of Deloitte & Touche LLP as independent auditor, and approval of a one-year extension of the Company's term. The filing presents vote tallies (For, Against, Withheld, Abstained, Broker Non-Votes) for each proposal, which is the core content of a shareholder vote results disclosure.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-07-22
Item 8.01
Summit announced updated overall survival (OS) results from the Phase III HARMONi clinical trial for ivonescimab, showing a hazard ratio of 0.76 in the June 2026 analysis with consistent efficacy across western and Asian patient populations. While this is clinical trial data rather than a formal earnings release or regulatory approval, the results are material to investors because they directly support the company's pending Biologics License Application (BLA) with a PDUFA goal date of November 14, 2026, and demonstrate progress toward potential FDA approval of the company's lead investigational therapy. The disclosure is operational/strategic in nature—reporting clinical development progress—rather than fitting a specific financial, governance, or legal category.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 97%
filed 2026-07-22
Item 5.07
Avanos Medical stockholders voted on July 22, 2026 to approve a merger agreement with American Industrial Partners affiliates at $25.00 per share in cash, with approximately 99.75% of shares voted in favor (35,119,793 for, 32,508 against, 55,248 abstain). The meeting also included a vote on executive compensation arrangements, with 30,620,395 shares in favor and 4,220,505 against.
View raw filing on EDGAR →
8-K
Exec departure
confidence 95%
filed 2026-07-22
Item 5.02
Casey Tansey, a Board member of 18+ years and early venture investor who led Inspire's Series A financing in 2007, notified the Company on July 16, 2026 of his decision to retire from the Board effective July 30, 2026. The Item 5.02 disclosure centers on his departure from the Board and decision not to stand for re-election, with no compensatory arrangements or new appointments disclosed. This is a material departure of a long-tenured director with significant historical influence on the company.
View raw filing on EDGAR →
8-K
Exec departure
confidence 95%
filed 2026-07-22
Item 5.02
Michael D. Garrison, Executive Vice President and President of the Medical Essentials and BioPharma Systems segments, informed BD of his intention to retire effective October 2, 2026, after more than 20 years with the company. The filing also discloses an organizational restructuring whereby BioPharma Systems will report directly to the CEO following his departure.
View raw filing on EDGAR →
8-K
Earnings release
confidence 99%
filed 2026-07-22
Item 2.02
Moody's Corporation announced its second quarter 2026 financial results on July 22, 2026, reporting revenue of $2.2 billion (up 15%), diluted EPS of $5.03 (up 57%), and updated full-year 2026 guidance with narrowed Adjusted Diluted EPS guidance to $16.50–$17.00.
View raw filing on EDGAR →
8-K
Earnings release
confidence 97%
filed 2026-07-22
Item 2.02
Wabtec issued a press release on July 22, 2026 reporting second quarter 2026 financial results with Q2 sales of $3.18B (+17.5% YOY), GAAP diluted EPS of $2.33 (+18.9% YOY), and adjusted diluted EPS of $2.76 (+21.6% YOY), along with raised full-year 2026 revenue and adjusted EPS guidance.
View raw filing on EDGAR →
8-K
Earnings release
confidence 99%
filed 2026-07-22
Item 2.02
Philip Morris International issued a press release on July 22, 2026 announcing its financial results for Q2 and first half-year ended June 30, 2026. The disclosure includes detailed results of operations with net revenues of $11.2 billion, adjusted diluted EPS of $2.20 (up 15.2%), and updated 2026 full-year guidance. This is a standard quarterly earnings release filed under Item 2.02 with exhibits containing the earnings announcement and supporting financial data.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-07-22
Item 2.02
Old National Bancorp issued a press release on July 22, 2026, reporting record second quarter 2026 financial results, including net income of $249.4 million and diluted EPS of $0.65. The disclosure is a standard quarterly earnings announcement with detailed financial metrics (net interest income, deposits, loans, credit quality, capital ratios) and is furnished as Exhibit 99.1 under Item 2.02, which is the standard Item for earnings releases.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-07-22
Item 2.02
Orrstown Financial Services issued a press release on July 21, 2026 reporting Q2 2026 earnings (quarter ended June 30, 2026) with net income of $21.2 million ($1.09 per diluted share) and a return on average assets of 1.53%.
View raw filing on EDGAR →
8-K
Dividend Distribution
confidence 85%
filed 2026-07-22
Item 7.01
The Board of Directors declared a $0.30 per common share cash dividend payable on August 11, 2026, as disclosed in the Regulation FD furnishing.
View raw filing on EDGAR →
8-K
Operational Other
confidence 85%
filed 2026-07-22
Item 8.01
Standard Nuclear disclosed substantial completion of construction at two new advanced nuclear fuel production facilities (SN-TN and SN-ID) in Tennessee and Idaho, along with regulatory approval of Preliminary Documented Safety Analyses from the U.S. Department of Energy. This represents a material operational and strategic milestone—the expansion of production capacity by up to 5 metric tons of uranium per year—that would affect a reasonable investor's assessment of the company's ability to execute its business plan and meet customer demand. While not fitting a specific named category, this is clearly an operational/strategic business event material to the registrant's growth trajectory.
View raw filing on EDGAR →
8-K
Earnings release
confidence 97%
filed 2026-07-22
Item 2.02
Five Star Bancorp issued a press release on July 22, 2026 announcing its second quarter 2026 financial results, disclosing net income of $19.4 million and earnings per share of $0.91, along with an investor presentation and scheduled earnings call for July 23, 2026.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-07-22
Item 2.02
NETSTREIT Corp. issued a press release on July 22, 2026 announcing its financial results for the second quarter ended June 30, 2026, disclosing net income of $0.06 per diluted share, AFFO of $0.35 per diluted share, investment activity of $298.9 million, and updated 2026 guidance.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-07-22
Item 2.02
Tesla disclosed its Second Quarter 2026 financial results on July 22, 2026, via a quarterly update posted to its website and furnished as Exhibit 99.1. The filing includes comprehensive financial statements showing Q2 2026 revenues of $28.2B (26% YoY growth), GAAP net income of $1.1B, and operational metrics including record vehicle deliveries of 480,126 units. This is a standard quarterly earnings release disclosure under Item 2.02.
View raw filing on EDGAR →
8-K
Dividend Distribution
confidence 95%
filed 2026-07-22
Item 8.01
The filing discloses Delek Logistics Partners' declaration of a quarterly cash distribution of $1.135 per common limited partner unit, payable August 10, 2026. This is a routine but material distribution announcement typical of master limited partnerships, affecting unitholder returns and investor valuation assessments.
View raw filing on EDGAR →
8-K
Governance Other
confidence 72%
filed 2026-07-22
Item 1.02
The termination of the Security Control Agreement by DCSA is a governance event reflecting the removal of foreign ownership/control mitigation measures following QIA's departure from the Company's Board of Directors. While the agreement's termination is administrative in nature, the underlying governance change (loss of board representation by a foreign investor) and the regulatory clearance it enables are material to investors assessing the Company's ownership structure and regulatory standing, particularly given BETA's apparent defense-sector exposure.
View raw filing on EDGAR →
8-K
Exec departure
confidence 92%
filed 2026-07-22
Item 5.02
Mingxiao (Gary) Guo, Senior Vice President and Chief Global Integrated Supply Chain Officer, is departing Trane Technologies effective August 1, 2026. The principal disclosed action is a named executive officer leaving the company. While the filing mentions a Separation Agreement and foregoing of clawback provisions, the core event is the departure itself, making exec_departure the most salient classification.
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-07-22
Item 8.01
Penske Automotive Group's Board received an unsolicited, preliminary non-binding proposal from Penske Corporation and Mitsui & Co., Ltd. to acquire all outstanding shares not already owned by them at $210 per share, implying an equity value of approximately $13.8 billion. This constitutes a material acquisition proposal that would result in a change of control, requiring disclosure under Item 8.01 as a material event. The Board has established a special committee to evaluate the proposal, and the transaction would eliminate the public float of the company.
View raw filing on EDGAR →
8-K
M&A activity
confidence 97%
filed 2026-07-22
Item 1.01
BioLife Solutions entered into a definitive Agreement and Plan of Merger with Repligen Corporation on July 21, 2026, whereby Repligen will acquire all outstanding shares of BioLife for $11.25 cash and 0.1442 shares of Repligen common stock per share (total enterprise value approximately $1.5 billion), with expected completion in Q4 2026 and unanimous board approval from both companies.
View raw filing on EDGAR →
6-K
Periodic Interim
confidence 95%
filed 2026-07-22
This is a Quarterly Management Statement for the six months ended 30 June 2026 — a half-year interim financial report. The document presents consolidated income statement, balance sheet summaries, credit quality metrics, capital and liquidity ratios, and forward guidance. Although it includes narrative commentary and highlights, the core substance is a periodic interim financial report, not a discrete event announcement. The filing date of 22 July 2026 and the statement's reference to a full Half Yearly Financial Report to be published on 7 August 2026 confirm this is the interim periodic disclosure itself.
View raw filing on EDGAR →
8-K
Earnings release
confidence 99%
filed 2026-07-22
Item 2.02
Alphabet disclosed its Q2 2026 financial results on July 22, 2026, including consolidated revenues of $119.8 billion (24% YoY growth), operating income of $40.8 billion (30% YoY growth), and diluted EPS of $9.11 (294% YoY growth). The press release, furnished as Exhibit 99.1, presents comprehensive quarterly financial statements and segment results, which is the core disclosure required under Item 2.02 (Results of Operations and Financial Condition).
View raw filing on EDGAR →
6-K
Dividend Distribution
confidence 95%
filed 2026-07-22
National Grid announces the operation of its Scrip Dividend Scheme for the 2025/26 final dividend payable on 23 July 2026, involving the issuance of 50,862,899 ordinary shares (49,766,614 shares at 1,197.70 pence per share plus 1,096,285 ordinary shares via ADRs at US$80.5453 per ADR). This is a material dividend distribution to shareholders, allowing them to elect to receive new shares in lieu of cash dividends.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-07-22
This 6-K announces FDA approval of Jideytro (zidesamtinib) for ROS1-positive NSCLC, GSK's first approved medicine in lung cancer. While the approval itself is a regulatory milestone and product launch event, it does not fit neatly into the discrete event categories (not an earnings release, M&A completion, impairment, or litigation). The disclosure is material—it represents a significant regulatory achievement and commercial milestone for GSK's oncology portfolio expansion strategy, particularly following the recently completed Nuvalent acquisition referenced in the filing.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 75%
filed 2026-07-22
Item 5.02
The filing discloses two executive transitions: Keith Regnante's resignation as CFO effective August 3, 2026, and Annita Tanini's appointment as interim principal financial officer and principal accounting officer effective August 4, 2026. While both events occur, the principal disclosed action centers on Tanini's appointment to the CFO role, including detailed compensation arrangements ($302,300 base salary, 30% bonus target, severance terms). The filing emphasizes her qualifications and new employment agreement, making the appointment the salient event, though Regnante's departure is also disclosed.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-07-22
Item 2.02
Medpace issued a press release on July 22, 2026 announcing financial results for the three and six months ended June 30, 2026, disclosing Q2 2026 revenue of $707.3 million (17.2% growth), GAAP net income of $121.4 million ($4.25 per diluted share), and full-year 2026 guidance. This is a standard quarterly earnings release furnished as Exhibit 99.1 under Item 2.02, materially affecting investor assessment of the company's financial performance and outlook.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-07-22
Item 3.02
Hawkeye Systems issued Common Stock Purchase Warrants to 15 accredited investors granting rights to purchase 14,000,000 shares of common stock at $.01 per share, with the warrants exercisable through December 31, 2026. The securities were offered in reliance on Section 4(a)(2) exemption and were unregistered, which is the hallmark of a private placement. This represents a dilutive issuance of equity securities outside the registered offering process, material to investors assessing capital structure and ownership dilution.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-22
Item 5.02
The filing discloses the appointment of three new directors—Gemma Hemsworth, Fiona Callering, and Alistair Pemberton—to the Board of Directors of OXO, Inc., effective immediately on July 22, 2026. This is a clear executive appointment event under Item 5.02, as the principal disclosed action is persons taking board roles. Board composition changes are material to investors' assessment of governance and strategic direction.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 95%
filed 2026-07-22
Item 5.07
Item 5.07 discloses the results of a shareholder vote (via written consent) in which 68.71% of voting power approved granting the Board discretionary authority to effect a reverse stock split in a 1-for-2 to 1-for-6 range. This is a classic shareholder vote result disclosure, material because reverse stock splits can affect share price, liquidity, and listing eligibility, and would influence a reasonable investor's assessment of the company's capital structure and exchange listing prospects.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-07-22
Item 5.07
This is a clear Item 5.07 disclosure of shareholder vote results from DXC Technology's 2026 Annual Meeting held on July 21, 2026. The filing reports certified voting outcomes on five proposals: election of nine directors, ratification of Deloitte & Touche LLP as auditor, advisory approval of named executive officer compensation, rejection of a term extension to the 2017 Omnibus Incentive Plan, and approval of a term extension to the 2017 Non-Employee Director Incentive Plan. The detailed vote tallies for each proposal are provided, making this a textbook shareholder_vote_results disclosure that is material to investors assessing governance and capital allocation decisions.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-22
Item 5.02
The filing discloses the appointment of Farrell Simon, Pharm.D., to Serina's Board of Directors effective July 22, 2026, with concurrent appointment to the Audit and Compensation Committees. Dr. Simon brings significant commercial and business development expertise from his role as Chief Commercial Officer at Trevi Therapeutics and prior decade at Pfizer, making this a material governance event affecting board composition and oversight capabilities at a clinical-stage biotech company.
View raw filing on EDGAR →
8-K
Earnings release
confidence 97%
filed 2026-07-22
Item 2.02
Wyndham Hotels & Resorts reported Q2 2026 financial results with net income of $102 million (up 17% YoY), adjusted EBITDA of $212 million (up 9% YoY), and diluted EPS of $1.36 (up 20% YoY), along with raised full-year 2026 guidance for adjusted EBITDA and adjusted diluted EPS.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-07-22
Item 2.02
Goosehead issued a press release on July 22, 2026 announcing Q2 2026 financial results, with total revenues of $113.4 million (up 21% year-over-year), net income of $17.0 million (up 105%), and adjusted EBITDA of $37.9 million (up 30%).
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-22
Item 5.02
The Board of Directors approved the appointment of Mark Jones, Jr., the Company's President and Chief Operating Officer, as CEO effective January 1, 2027, to succeed retiring CEO Mark Miller.
View raw filing on EDGAR →
8-K
Earnings release
confidence 97%
filed 2026-07-22
Item 2.02
Essential Properties Realty Trust disclosed its financial results for the three and six months ended June 30, 2026, including net income per share of $0.34 for Q2, AFFO per share of $0.50, and FFO per share of $0.53, along with updated 2026 guidance for AFFO ($2.01–$2.05 per share) and investment volume ($1.2–$1.5 billion).
View raw filing on EDGAR →
8-K
M&A activity
confidence 99%
filed 2026-07-22
Item 1.01
Greenbacker Renewable Energy Co LLC entered into a definitive Agreement and Plan of Merger on July 21, 2026, whereby MN8 Energy Holdings LLC will acquire Greenbacker in a cash-and-equity transaction valued at approximately $375 million, with Greenbacker becoming a wholly owned subsidiary of MN8 Energy. The transaction represents a material change of control and strategic combination creating a top-tier American power platform with combined capacity exceeding 6 GW.
View raw filing on EDGAR →
8-K
Earnings release
confidence 97%
filed 2026-07-22
Item 2.02
Interparfums disclosed net sales results for the second quarter and six months ended June 30, 2026, with Q2 net sales of $341M and H1 net sales of $686M, including detailed segment and brand performance analysis and management commentary on business performance.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-07-22
Item 5.07
ChargePoint held its 2026 Annual Meeting of Stockholders on July 21, 2026, with shareholders voting on three proposals: election of Class III directors (Bruce Chizen, Michael Linse, and Richard Wilmer), ratification of PricewaterhouseCoopers LLP as independent auditor, and advisory approval of named executive officer compensation. Final vote tallies certified by the Inspector of Election are disclosed.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 95%
filed 2026-07-22
Item 5.07
This is a classic Item 5.07 disclosure reporting the results of WM Technology's 2026 Annual Meeting of Stockholders held on July 16, 2026. The filing presents voting outcomes for four proposals: (1) declassification of the board (failed), (2) advisory say-on-pay vote (passed), (3) auditor ratification (passed), and (4) election of three Class II directors (passed). The detailed vote tallies and quorum information (84% attendance) are material to shareholders assessing governance and board composition.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-07-22
Item 2.02
Otis issued a press release on July 22, 2026 announcing its second quarter 2026 financial results, including net sales of $3.9 billion (up 7%), GAAP EPS of $1.12 (up 13%), and adjusted EPS of $1.01 (down 4%), along with segment performance, cash flow, and full-year outlook revisions. This is a standard quarterly earnings disclosure furnished as Exhibit 99 under Item 2.02.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 95%
filed 2026-07-22
Item 1.01
Hillman Solutions completed a refinancing of its credit facilities on July 22, 2026, entering into a new $735 million senior secured Term Loan B and a $375 million asset-based revolving credit facility. The Term Credit Agreement and ABL Credit Agreement represent the creation of new direct financial obligations used to refinance and replace existing debt, extending maturities to 2033 and 2031 respectively. This is a material capital structure event affecting the company's debt profile and financial flexibility.
View raw filing on EDGAR →
8-K
Governance Other
confidence 75%
filed 2026-07-22
Item 8.01
Black Hawk Acquisition Corp has deposited $150,000 into its trust account to extend the deadline for completing its initial business combination by one month (from July 22, 2026 to August 22, 2026). This is a governance and structural matter related to the SPAC's timeline and shareholder protections, disclosed under Item 8.01 (Other Events). While not a named governance event type, it is material to shareholders as it affects the company's ability to consummate a business combination and the timeline for potential return of capital.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-07-22
Item 8.01
The Company received notification from OTC Markets Group that its common stock has been moved to the OTC Expert Market on an unsolicited quotes only basis. This represents a material downgrade in listing status and a significant delisting risk event, as movement to the OTC Expert Market typically indicates failure to meet continued listing standards and substantially reduces liquidity and investor access to the stock.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-07-22
Item 3.02
The Company disclosed an unregistered sale of approximately 1,168,937 common shares for ~$29 million pursuant to subscription agreements with accredited investors, relying on Section 4(a)(2) and Regulation D exemptions. This is a classic dilutive equity issuance under Item 3.02, material to investors assessing capital structure and ownership dilution.
View raw filing on EDGAR →
6-K
Governance Other
confidence 92%
filed 2026-07-22
EX-99.1
The exhibit announces a corporate name change from "Gambling.com Group Limited" to "Grandstand Limited" effective July 23, 2026, with a corresponding ticker symbol change from GAMB to GRSD. While primarily a rebranding and governance matter, the announcement emphasizes the company's strategic evolution and portfolio diversification since its 2021 IPO. This is a material governance event affecting the company's public identity and market listing, though it does not fit the specific governance categories (exec appointment/departure, compensation, shareholder vote results, or auditor change).
View raw filing on EDGAR →
6-K
Earnings release
confidence 98%
filed 2026-07-22
EX-99.1
This is a press release announcing Oatly's second quarter 2026 financial results, including revenue of $240.1 million (15.2% increase), gross margin of 33.9%, net loss of $31.3 million (improved from $55.9 million prior year), and Adjusted EBITDA of $0.4 million (improved from loss of $3.6 million). The company also raised its 2026 constant-currency revenue growth outlook from +3% to +5% to +8% to +10%. This is a material earnings disclosure affecting investor assessment of the registrant's financial performance and outlook.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 92%
filed 2026-07-22
Item 7.01
Galaxy Digital announced its intention to offer $3.507 billion aggregate principal amount of senior secured notes due 2031 through its subsidiary Galaxy Helios Data Centers II LLC. This constitutes creation of a new direct financial obligation—a material debt issuance. The filing explicitly states the notes will be offered in a private placement to qualified institutional buyers under Rule 144A and to non-U.S. persons under Regulation S, with proceeds designated for financing data center development and construction in Texas.
View raw filing on EDGAR →